Drug intelligence / Profile preview

NIT 002

Development stage: Preclinical
Lead developer: NOVAiCOS Immunotherapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Percutaneous

Overview

**NIT 002** is a preclinical, ICOS-Fc-based local therapeutic formulation being developed by NOVAiCOS Immunotherapeutics as a bioactive bone cement for bone metastases and pathological fractures. The product is designed to deliver recombinant ICOS-Fc from an injectable, resorbable cement matrix. ICOS-Fc binds and triggers inducible T-cell co-stimulator ligand signaling, producing anti-osteoclastogenic activity that reduces bone resorption; the broader ICOS-Fc platform has also been described as immunomodulatory and antitumor. ([novaicos.com](https://novaicos.com/pipeline/))

Targets

ICOSLG (Inducible T-cell Co-stimulator Ligand)

Beyond the preview

Go deeper on NIT 002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIT 002.

Explore the full profile